Insider · CIK 0001229592
Steven Gillis
Files at TAK (TAKEDA PHARMACEUTICAL CO LTD), SANA (Sana Biotechnology, Inc.), BOLD (Boundless Bio, Inc.), LYEL (Lyell Immunopharma, Inc.), NMRA (Neumora Therapeutics, Inc.), PRME (Prime Medicine, Inc.), RAPP (Rapport Therapeutics, Inc.), MTSR (Metsera, Inc.), SPTX (Seaport Therapeutics, Inc.), KARD (Kardigan, Inc.). First filing -, latest -.
In brief
Steven Gillis files SEC Form 4 as 10% owner and director at TAK (TAKEDA PHARMACEUTICAL CO LTD), and also at SANA (Sana Biotechnology, Inc.), BOLD (Boundless Bio, Inc.), LYEL (Lyell Immunopharma, Inc.), NMRA (Neumora Therapeutics, Inc.) and 5 more. No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Steven Gillis has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award Ordinary Shares | +3,800 | $0.00 | $0 | 10,400 | Jul 6, 2026 |
| Jul 10, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | DDisposition to issuer Tax Obligation Awardderivative | -1,152 | $4,931.20 | $5.7M | 0 | Jul 6, 2026 |
| Jul 1, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award Tax Obligation Awardderivative | +1,319 | $0.00 | $0 | 1,319 | Jul 6, 2026 |
Questions about Steven Gillis
Answered from the filings on this page, as of the latest one.
Is Steven Gillis buying or selling?
Steven Gillis has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Steven Gillis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steven Gillis has 0.
Where does Steven Gillis file Form 4?
Steven Gillis has filed Form 4 at TAK (TAKEDA PHARMACEUTICAL CO LTD); SANA (Sana Biotechnology, Inc.); BOLD (Boundless Bio, Inc.); LYEL (Lyell Immunopharma, Inc.); NMRA (Neumora Therapeutics, Inc.) and 5 more. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.